Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility

Avantor (NYSE: AVTR) expanded its St.

Rhea-AI Summary

Avantor (NYSE: AVTR) expanded its St. Louis site on April 13, 2026, adding GMP-aligned microbial testing and ICH-compliant stability testing and storage to strengthen U.S. biomanufacturing support.

The upgrade localizes testing previously done externally, supports 2,000+ microbial samples annually, aims to speed turnaround, improve data visibility, and reduce supply chain complexity for regulated biopharma applications.

Positive

• Supports 2,000+ microbial samples annually
• GMP-aligned microbial testing and ICH-compliant stability testing added
• Localizes testing, reducing reliance on third-party and cross-border labs
• Designed audit-ready lab space and advanced stability storage for APIs and excipients

Negative

• None.

Argus Apr 13 session

+3.54% close to close Open Argus

Details

News Market Reaction – AVTR

In the Apr 13 session, AVTR gained 3.54%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Avantor’s continued execution of its “Revival” agenda by expanding GMP-...

Analysis

This announcement highlights Avantor’s continued execution of its “Revival” agenda by expanding GMP-aligned microbial and ICH-compliant stability testing at its St. Louis site, supporting over 2,000 microbial samples annually and consolidating U.S. quality infrastructure. The move builds on earlier 2025 results and strategic updates that emphasized supply chain and service upgrades. Investors may watch how these localized capabilities affect turnaround times, customer adoption and future commentary in earnings or regulatory filings.

Key Figures

Microbial sample capacity: 2,000+ samples annually 2025 Revenue: $6.55B 2025 Adjusted EBITDA: $1.07B +3 more

Microbial sample capacity

2,000+ samples annually

St. Louis facility internal network support

2025 Revenue

$6.55B

Full-year 2025 results (earnings release)

2025 Adjusted EBITDA

$1.07B

Full-year 2025 (proxy statement)

2025 Adjusted EPS

$0.90

Full-year 2025 (earnings and proxy)

2025 Free Cash Flow

$496M

Full-year 2025 (proxy statement)

Adjusted Net Leverage

3.2x

Year-end 2025 (proxy statement)

Historical Context

5 past events · Latest: Apr 01

5 events

1. Apr 01

   CFO transition

   24h Move

   -0.9%

   CFO departure with interim appointment and 2026 guidance reaffirmed.

2. Feb 11

   Earnings & strategy

   24h Move

   -13.6%

   2025 sales decline, GAAP net loss and launch of Revival turnaround program.

3. Jan 15

   Dividend update

   24h Move

   +1.2%

   IVR declared monthly dividend and provided book value and leverage update.

4. Jan 12

   Earnings date set

   24h Move

   -1.1%

   Announcement of timing for Q4 and full-year 2025 earnings release and call.

5. Jan 05

   Conference appearance

   24h Move

   +3.8%

   Planned presentation at J.P. Morgan Healthcare Conference with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gmp-aligned, ich-compliant

2 terms

gmp-aligned regulatory

"Expands GMP-aligned microbial testing and ICH-compliant stability testing and storage"

GMP-aligned means a company’s manufacturing systems, processes and documentation follow Good Manufacturing Practice standards used to ensure products are made consistently, safely and meet quality requirements for drugs, medical devices or related goods. For investors, GMP alignment lowers the chance of regulatory fines, product holds or costly recalls; think of it like a factory having certified safety and quality checkpoints so shipments run smoothly and revenue is less likely to be disrupted.

ich-compliant regulatory

"Expands GMP-aligned microbial testing and ICH-compliant stability testing and storage"

ICH-compliant means that a company’s drug development, testing or manufacturing follows the technical and safety guidelines set by the International Council for Harmonisation (ICH), a global body that aligns regulators across major markets. For investors, ICH compliance is like having paperwork and quality checks in order across countries: it lowers the chance of delays, costly rework or rejection by regulators and therefore reduces development and approval risk for pharmaceutical products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

St. Louis site strengthens integrated support for biopharma manufacturing

RADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site.

The investment builds on Avantor's established global quality infrastructure, expanding and localizing capabilities to better support U.S.-based biopharma manufacturing and further accelerate service for customers.

Key Highlights

• Expands GMP-aligned microbial testing and ICH-compliant stability testing and storage in North America
• Localizes testing previously conducted across third-party labs and Avantor's global network, bringing critical capabilities closer to U.S. manufacturing operations
• Supports 2,000+ microbial samples annually within Avantor's internal network
• Enables faster turnaround times, improved data visibility, and reduced supply chain complexity

Expanding and Consolidating U.S. Quality Infrastructure
The enhanced St. Louis facility now offers integrated microbial and stability testing aligned with global regulatory standards, supporting regulated biopharma applications and reinforcing Avantor's commitment to quality, compliance, and customer service.

By consolidating these capabilities into a single North American location, Avantor reduces reliance on external laboratories and minimizes cross-border sample movement, improving efficiency while maintaining consistent global quality standards.

Improving Speed, Control and Supply Chain Efficiency
Integrating testing into one location enables accelerated time to market, more interconnected lab compliance and in-house expertise, and more streamlined operations across the biopharma supply chain.

Leadership Perspective
"Expanding our quality control capabilities in North America strengthens our manufacturing and supply chain infrastructure and will help us deliver our high-quality chemicals and other products to customers faster," said Mary Blenn, Chief Operating Officer at Avantor. "As part of our Revival program, we are making significant investments in our global supply chain and quality capabilities, all with a focus on reducing risk, accelerating timelines and delivering more value to our customers."

Facility Designed for Compliance and Transparency
The facility is designed to support customer transparency and regulatory needs, including audit-ready laboratory space, advanced stability storage for high-value materials such as APIs and excipients, and capabilities that support more efficient, centralized testing and faster product development timelines.

For more information, read the full story here.

About Avantor
Avantor^® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

Investor Relations Contact
Chris Fidyk
Vice President, Investor Relations
Avantor
Chris.Fidyk@avantorsciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-enhances-us-biomanufacturing-infrastructure-with-expanded-stability-and-microbial-testing-facility-302739432.html

SOURCE Avantor and Financial News

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avantor (AVTR) announce on April 13, 2026 about its St. Louis facility?

Avantor announced the St. Louis site expansion adding GMP microbial and ICH stability testing. According to the company, this localizes testing, supports 2,000+ microbial samples annually, and aims to accelerate turnaround and reduce supply chain complexity for U.S. biopharma customers.

How many microbial samples will Avantor (AVTR) support annually after the St. Louis expansion?

The facility will support more than 2,000 microbial samples annually. According to the company, this capacity is within Avantor's internal network and reduces dependence on external and cross-border laboratories, improving sample handling and data visibility.

Will Avantor's St. Louis testing meet regulatory standards for biopharma manufacturers?

Yes — the St. Louis site offers GMP-aligned microbial testing and ICH-compliant stability testing. According to the company, the facility is designed for audit-ready operations to support regulated biopharma applications and customer regulatory needs.

How will Avantor's (AVTR) St. Louis expansion affect turnaround times for biopharma testing?

The expansion is expected to accelerate testing turnaround and reduce supply chain complexity. According to the company, consolidating tests locally enables faster results, improved data visibility, and fewer cross-border sample movements for U.S. manufacturing operations.

What types of materials will Avantor's new stability storage support at the St. Louis site?

The stability storage will support high-value materials such as APIs and excipients. According to the company, the advanced storage is designed to meet regulatory needs and enable more centralized, audit-ready stability testing for product development timelines.

How does the St. Louis upgrade fit into Avantor's broader Revival program and supply chain strategy?

The expansion aligns with Avantor's Revival program to invest in supply chain and quality capabilities. According to the company, the move focuses on reducing risk, accelerating timelines, and delivering greater value by strengthening North American quality infrastructure.